TARPLIN, DOWNS & YOUNG, LLC

Lobbying for HANSA BIOPHARMA · Biopharmaceutical company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $60,000.00 income · posted Oct 15, 2025

Lobbying activity 2

Health Issues

Kidney issues, access to innovation, rare disease issues, organ rejection

Budget/Appropriations

Federal budget issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.